hotspot -WSS

hotspot

author：leisure time 2025-09-29 16:35:24 - browse：6

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Cancer drug shortages' outsize impact on ovarian cancer patients

leisure time

WSS

Can food be medicine? And other questions about a new push

Doctor appointment wait times are getting worse

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Baltimore teen accused of firing into crowd during block party mass shooting

A new study asks: Are we harming blood donors by taking blood?

Listen: Biogen's messy board & Laronde's data problem

Wikipedia

hotspot

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Trump's false claims about Georgia's 2020 election long debunked

Peter Hotez and the public health issue of online harassment

Listen: Racing for gene therapy & a pioneering approval

Activists slam private health insurers over coverage restrictions

Living with Hashimoto's and celiac disease, and med school, too

In age of alternative facts, a scholarly course on calling out crap

Make 'food is medicine' a key part of White House nutrition meeting

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ActiGraph execs on goal of drug approvals with digital endpoints

hotspot

Lung cancer is America's deadliest cancer. Yet so few get screened

Grail is spending more than ever lobbying Congress

Patient advocates sound warning on FDA proposal on salt intake

Listen: Biogen's messy board & Laronde's data problem

Cancer drug shortages' outsize impact on ovarian cancer patients

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

explore

leisure time

leisure time

knowledge